280 related articles for article (PubMed ID: 33708212)
1. Treg and Oligoclonal Expansion of Terminal Effector CD8
Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
Front Immunol; 2021; 12():620596. PubMed ID: 33708212
[TBL] [Abstract][Full Text] [Related]
2. Mass Cytometry Discovers Two Discrete Subsets of CD39
Marsh-Wakefield F; Kruzins A; McGuire HM; Yang S; Bryant C; Fazekas de St Groth B; Nassif N; Byrne SN; Gibson J; Brown C; Larsen S; McCulloch D; Boyle R; Clark G; Joshua D; Ho PJ; Vuckovic S
Front Immunol; 2019; 10():1596. PubMed ID: 31428081
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
Vuckovic S; Bryant CE; Lau KHA; Yang S; Favaloro J; McGuire HM; Clark G; de St Groth BF; Marsh-Wakefield F; Nassif N; Abadir E; Vanguru V; McCulloch D; Brown C; Larsen S; Dunkley S; Khoo L; Gibson J; Boyle R; Joshua D; Ho PJ
Blood Adv; 2020 Oct; 4(19):4593-4604. PubMed ID: 32986791
[TBL] [Abstract][Full Text] [Related]
4. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the role of Tregs in the progression of multiple myeloma.
Lad D; Huang Q; Hoeppli R; Garcia R; Xu L; Levings M; Song K; Broady R
Leuk Lymphoma; 2019 Sep; 60(9):2134-2142. PubMed ID: 30773086
[TBL] [Abstract][Full Text] [Related]
6. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
Frassanito MA; Ruggieri S; Desantis V; Di Marzo L; Leone P; Racanelli V; Fumarulo R; Dammacco F; Vacca A
Eur J Haematol; 2015 Jul; 95(1):65-74. PubMed ID: 25409753
[TBL] [Abstract][Full Text] [Related]
7. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
[TBL] [Abstract][Full Text] [Related]
8. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
9. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
10. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
Miguel-Garcia A; Matutes E; Tarin F; Garcia-Talavera J; Miguel-Sosa A; Carbonell F; Catovsky D
J Clin Pathol; 1995 Sep; 48(9):835-9. PubMed ID: 7490317
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.
Bonanno G; Mariotti A; Procoli A; Folgiero V; Natale D; De Rosa L; Majolino I; Novarese L; Rocci A; Gambella M; Ciciarello M; Scambia G; Palumbo A; Locatelli F; De Cristofaro R; Rutella S
J Transl Med; 2012 Dec; 10():247. PubMed ID: 23232072
[TBL] [Abstract][Full Text] [Related]
12. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
[TBL] [Abstract][Full Text] [Related]
13. Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study.
Wang JN; Cao XX; Zhao AL; Cai H; Wang X; Li J
Cancer Cell Int; 2018; 18():187. PubMed ID: 30479566
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
15. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Goodyear OC; Pratt G; McLarnon A; Cook M; Piper K; Moss P
Blood; 2008 Oct; 112(8):3362-72. PubMed ID: 18658027
[TBL] [Abstract][Full Text] [Related]
16. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
17. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
18. IL-10 inducible CD8
Plaumann J; Engelhardt M; Awwad MHS; Echchannaoui H; Amman E; Raab MS; Hillengass J; Halama N; Neuber B; Müller-Tidow C; Goldschmidt H; Hundemer M
Cancer Immunol Immunother; 2018 Nov; 67(11):1695-1707. PubMed ID: 30128739
[TBL] [Abstract][Full Text] [Related]
19. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
Bae J; Accardi F; Hideshima T; Tai YT; Prabhala R; Shambley A; Wen K; Rowell S; Richardson PG; Munshi NC; Anderson KC
Leukemia; 2022 Jan; 36(1):138-154. PubMed ID: 34290359
[TBL] [Abstract][Full Text] [Related]
20. The T Cell in Myeloma.
Joshua D; Suen H; Brown R; Bryant C; Ho PJ; Hart D; Gibson J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):537-542. PubMed ID: 27601001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
